Evidence map›Paper›PMID 36976674›Full record

ReviewNeurology international2023

Chronic Administration of Melatonin: Physiological and Clinical Considerations.

Donald Givler, Amy Givler, Patrick M Luther, Danielle M Wenger, Shahab Ahmadzadeh, Sahar Shekoohi, Amber N Edinoff, Bradley K Dorius, Carlo Jean Baptiste, Elyse M Cornett and 2 more

Open access · goldAbstract readReview
In one paragraph

Review in Neurology international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 3 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Review
  12. The Pinealoprive Syndrome: Myth or Reality?Advances and technical standards in neurosurgery · 2026
    Review
  13. Review
  14. Article
  15. Article
  16. Protective Effect of Melatonin Against Bisphenol A Toxicity.International journal of molecular sciences · 2025
    Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Donald GivlerDepartment of Family Medicine, Louisiana State University Health Sciences Center at Shreveport/Monroe, Monroe, LA 71210, USA.
Amy GivlerDepartment of Family Medicine, Louisiana State University Health Sciences Center at Shreveport/Monroe, Monroe, LA 71210, USA.
Patrick M LutherSchool of Medicine, Louisiana State University Health Sciences Center at Shreveport, 1501 Kings Highway, Shreveport, LA 71103, USA.
Danielle M WengerCollege of Medicine-Phoenix, University of Arizona, 475 N 5th St., Phoenix, AZ 85004, USA.ORCID 0000-0002-1375-2872
Shahab AhmadzadehDepartment of Anesthesiology, Louisiana State University Health Sciences Center at Shreveport, 1501 Kings Highway, Shreveport, LA 71103, USA.
Sahar ShekoohiDepartment of Anesthesiology, Louisiana State University Health Sciences Center at Shreveport, 1501 Kings Highway, Shreveport, LA 71103, USA.
Amber N EdinoffHarvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA.ORCID 0000-0001-7436-6206
Bradley K DoriusDepartment of Anesthesiology, Louisiana State University Health Sciences Center at Shreveport, 1501 Kings Highway, Shreveport, LA 71103, USA.
Carlo Jean BaptisteDepartment of Anesthesiology, Louisiana State University Health Sciences Center at Shreveport, 1501 Kings Highway, Shreveport, LA 71103, USA.
Elyse M CornettDepartment of Anesthesiology, Louisiana State University Health Sciences Center at Shreveport, 1501 Kings Highway, Shreveport, LA 71103, USA.ORCID 0000-0001-7961-3931
Adam M KayeDepartment of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA 95211, USA.ORCID 0000-0002-7224-3322
Alan D KayeDepartment of Anesthesiology, Louisiana State University Health Sciences Center at Shreveport, 1501 Kings Highway, Shreveport, LA 71103, USA.
Louisiana State University Health Sciences Center Shreveport · USUniversity of the Pacific · USHarvard University · USUniversity of Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExogenous melatonin is commonly used to treat insomnia, other sleep problems, and numerous medical illnesses, including Alzheimer's disease, autism spectrum disorder, and mild cognitive impairment in adults and children. There is evolving information regarding issues with the use of chronic melatonin.

methodsThe present investigation was a narrative review.

resultsMelatonin usage has risen dramatically in recent years. Many countries only allow melatonin prescriptions. In the United States (U.S.), it is classified as a dietary supplement accessible over the counter and can be derived from animals, microorganisms, or, most commonly, made synthetically. No regulatory agency oversees its manufacturing or sale in the U.S. melatonin concentration of marketed preparations varies widely between product labels and manufacturers. Melatonin's ability to induce sleep is detectable. However, it is modest for most people. Sleep length appears to be less important in sustained-release preparations. The optimal dosage is unknown, and routinely used amounts vary substantially. Melatonin's short-term negative effects are minimal, resolve at medicine cessation, and do not usually prevent usage overall. Much research on long-term melatonin administration has found no difference between exogenous melatonin and placebo in terms of long-term negative effects.

conclusionMelatonin at low to moderate dosages (approximately 5-6 mg daily or less) appears safe. Long-term usage appears to benefit certain patient populations, such as those with autism spectrum disorder. Studies investigating potential benefits in reducing cognitive decline and increased longevity are ongoing. However, it is widely agreed that the long-term effects of taking exogenous melatonin have been insufficiently studied and warrant additional investigation.

Indexed as

agingautistic spectrum disorderdietary supplementinsomniamelatoninsleep

Identifiers

PMID36976674
PMCPMC10053496
OpenAlexW4327621771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.